General Oncology, Inc.
- Biotech or pharma, therapeutic R&D
General Oncology is a biopharmaceutical company developing GO-4, a phase 1 asset demonstrating a substantial signal of efficacy against BRCA-mutated pancreatic cancer, with a median PFS of at least 14.2 months in patients similar to those expected to be enrolled in the upcoming phase 2 potentially pivotal study (median not yet reached; range: 4.9–42.1 months). The company was founded by Arnold Glazier, M.D., who pioneered treating BRCA-mutated pancreatic cancer with DNA-crosslinking therapy supported by stem cell infusion, leading to the cure of his sister (now 13 years cancer-free) without any lasting side effects.
The company also has a deep pipeline of novel ultra-high potency small molecule compounds designed to treat metastatic and refractory cancers.
For more information about General Oncology, please visit www.generaloncology.com.
Address
BrooklineMassachusetts
United States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}